Medtronic Announces FDA Approval of Protecta Implantable Defibrillators That Reduce Inappropriate Shocks

Medtronic, Inc. MDT today announced U.S. Food and Drug Administration (FDA) approval of the Protecta portfolio of implantable cardioverter-defibrillatorsand cardiac resynchronization therapy-defibrillators. The new family of implantable defibrillators features SmartShock™ Technology, which includes six new Medtronic-exclusive algorithms that recognize life-threatening arrhythmias and deliver therapeutic shocks only when appropriate,¹ therefore enhancing patient quality of life.2 Findings from the Virtual ICD study, based on a statistical model, shows that 98 percent of patients with SmartShock Technology will be free of inappropriate shocks one year after implant and 92 percent will be free of inappropriate shocks five years after implant.1 Shipments of the Protecta portfolio of products will begin immediately.